XenoPort Provides Update on Availability of Horizant

  XenoPort Provides Update on Availability of Horizant

               Anticipates Product in Pharmacies in Early June

Business Wire

SANTA CLARA, Calif. -- May 17, 2013

XenoPort, Inc. (Nasdaq: XNPT) announced today that shipments of Horizant^®
(gabapentin enacarbil) Extended-Release Tablets to its distributor in the
United States have commenced. Depending on individual pharmacy ordering
patterns, the product is anticipated to be generally available to patients in
the first week of June.

“We are pleased that the issues related to manufacturing have been resolved
and that product has now been shipped to our distribution center, which will
be filling orders from wholesalers shortly,” commented Ronald W. Barrett,
Ph.D., chief executive officer of XenoPort. “We have received inquiries from
patients and physicians about the status of Horizant, hence our desire to make
today’s announcement.”

On May 1, 2013, XenoPort re-acquired from GlaxoSmithKline (GSK) all
commercialization rights to Horizant. Prior to the reacquisition of Horizant,
GSK experienced manufacturing issues and delays that have resulted in a
stockout of the product.

About Horizant (gabapentin enacarbil)

Gabapentin enacarbil is a patented molecule that was discovered and developed
by XenoPort. It utilizes XenoPort’s Transported Prodrug technology that was
designed to take advantage of high-capacity transport mechanisms in the
gastrointestinal tract to offer efficient absorption and extended exposure of
gabapentin. (Horizant is not interchangeable with other gabapentin products.)

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant, XenoPort’s
internally discovered drug, is approved and being marketed by XenoPort in the
United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is
approved and is being marketed in Japan. Astellas Pharma Inc. holds all
development and commercialization rights for Regnite in Japan and five other
Asian countries. XenoPort holds all other world-wide rights to gabapentin
enacarbil. XenoPort's pipeline of product candidates includes potential
treatments for patients with spasticity, Parkinson's disease,
relapsing-remitting multiple sclerosis and psoriasis.

Forward-Looking Statements

This press release contains “forward-looking” statements, including, without
limitation, all statements related to the availability of Horizant to patients
and the timing thereof. Any statements contained in this press release that
are not statements of historical fact may be deemed to be forward-looking
statements. Words such as “anticipated,” “potential,” “will” and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements are based upon XenoPort's current expectations.
Forward-looking statements involve risks and uncertainties. XenoPort's actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to XenoPort’s
lack of commercialization experience and its ability to establish, or contract
with third parties to establish, distribution, manufacturing, supply chain and
other sufficient capabilities to manufacture and distribute Horizant and
XenoPort’s ability to obtain uninterrupted drug supply. These and other risk
factors are discussed under the heading “Risk Factors” in XenoPort’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2013, filed with the
Securities and Exchange Commission on April 24, 2013. XenoPort expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any
change in the company's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.

Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.